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 A new family of indole-containing arene ruthenium organometallic compounds are active 
against several bacterial species and drug resistant strains 
 Bactericidal activity observed against various Gram negative, Gram positive and acid-fast 
bacteria, demonstrating broad-spectrum inhibitory activity 
 Compound series exhibits low toxicity against human cells 





         
Abstract 
Antimicrobial resistant (AMR) bacteria are emerging and spreading globally, threatening our ability 
to treat common infectious diseases. The development of new classes of antibiotics able to kill or 
inhibit the growth of such AMR bacteria through novel mechanisms of action is therefore urgently 
needed. Here, a new family of indole-containing arene ruthenium organometallic compounds are 
screened against several bacterial species and drug resistant strains. The most active complex [(p-
cym)Ru(O-cyclohexyl-1H-indole-2-carbothioate)Cl] (3) shows growth inhibition and bactericidal 
activity against different organisms (Acinetobacter baumannii, Mycobacterium abscessus, 
Mycobacterium tuberculosis, Staphylococcus aureus, Salmonella enterica serovar typhi and 
Escherichia coli), demonstrating broad-spectrum inhibitory activity. Importantly, this compound 
series exhibits low toxicity against human cells. Owing to the novelty of the antibiotic family, their 
moderate cytotoxicity, and their inhibitory activity against Gram positive, Gram negative and acid-








Antibiotic resistance is a worldwide threat to public health, food security, and economic and societal 
developments.1 The prevalence of antimicrobial resistance (AMR) among common pathogens is 
rapidly increasing, which leads to widespread diseases becoming harder, or impossible, to cure. AMR 
organisms of interest include Acinetobacter baumannii, Escherichia coli, Salmonella sp. and several 
other multidrug-resistant Gram-negative organisms.2 In the last decades, a global effort has allowed 
the development of new antibiotic drugs with activity against common AMR organisms,3 but 
resistance against such agents is already emerging. There is therefore an urgent need to find new 
families of compounds with high levels of antibacterial activity, novel mechanisms of action and low 
frequencies of antibiotic resistance. 
Inorganic metallodrugs offer potential for unique mechanisms of drug action based on the choice of 
the metal, its oxidation state, the types and number of coordinated ligands and the coordination 
geometry.4, 5 As such, medicinal inorganic chemistry provides a rich platform in the pharmacological 
space for structural and electronic diversity.6 Medicinal inorganic chemistry has been stimulated by 
the success of platinum anticancer drugs (used as a component of nearly 50% of all cancer 
chemotherapy treatments), by the use of gadolinium(III) complexes as MRI contrast agents (about 
20 million doses administered per year), and of the radionuclide 99m-technetium 
radiopharmaceuticals for γ-ray imaging (used in about 20 million radio diagnostic procedures each 
year).7-10 However, the involvement of metals in many other diseases and conditions is of current 
interest in relation to their causes, their treatment or detection, including neurodegeneration,11 
         
fungal12, parasitic,13, 14 viral15 infections and inflammation.16 In the last decades, a wide range of 
inorganic and organometallic compounds have been investigated for killing or inhibiting microbial 
growth.17-33  
The antimicrobial activity of some half-sandwich “piano-stool” complexes of precious metals (Ru, Os, 
Rh, Ir) has very recently proven to be highly promising in our current fight against AMR, with 
demonstrated potency against drug-resistant strains of Mycobacterium tuberculosis.34 Half-sandwich 
complexes are versatile and highly modifiable organometallics, which contains a π-bonded neutral 
arene or negatively charged cyclopentadienyl ligand, and, usually, one monodentate and one 
bidentate ligand. The monodentate and bidentate ligands allow further structural and electronic 
control of reactivity, including the incorporation of bio-active moieties.  
We have recently developed an interest in investigating the effect of bio-active indole moieties as 
bidentate ligands on the biological properties of half-sandwich metal complexes.35 Indoles are 
bicyclic heterocycles that are commonly found in plants, bacteria and animals. Natural and synthetic 
indole-based compounds have widely been used as antibacterial, antifungal, anti-inflammatory, 
antihistaminic and anticancer drugs.36, 37 Examples of such compounds currently in clinical use are 
the non-steroidal anti-inflammatory drug indomethacin38 or the antiretroviral delavirdine.39 
 
Scheme 1. Preparation of the indole-based ligands L6 – L9 and complexes 1 – 4. 
Herein, we report the synthesis and characterisation of a new family of four ruthenium half-
sandwich complexes containing O-R-1H-indole-2-carbothioate (O-R-ind-th; R = methyl, ethyl, 
cyclohexyl, phenyl) [(p-cym)Ru(O-Me-ind-th)Cl] (1), [(p-cym)Ru(O-Et-ind-th)Cl] (2),  [(p-cym)Ru(O-Cy-
ind-th)Cl] (3), [(p-cym)Ru(O-Ph-ind-th)Cl] (4) (Scheme 1). Their stability in solution, hydrolysis rates 
and acid dissociation constants are studied, along with toxicity data on three human cell lines for 
both ligands and complexes. The bactericidal activity of the four ligands and complexes against 
several drug resistant isolates of Escherichia coli (E. coli J53 2138, a clinical isolate producing the 
         
extended spectrum β-lactamase (ESBL) OXA-1, which confers resistance to ampicillin, ticarcillin, 
piperacillin and cephalosporins, E. coli J53 2140E, producing the ESBL OXA-3) is reported.  
 
 
Results and discussions 
Synthesis, stability in solution, aquation and pKa determination 
The indole 2-carboxylate ligands L2 – L5 were synthesised by esterification of 1H-indole-2-carboxylic 
acid (L1) with the corresponding alcohol (MeOH, EtOH, CyOH, PhOH, respectively). Thiolation of the 
carboxylic group of ligands L2 – L5 was performed by refluxing the corresponding ligands with the 
Lawesson’s reagent in toluene to yield the O-R-1H-indole-2-carbothioate ligands L6 – L9 (R = methyl, 
ethyl, cyclohexane, benzene; Scheme 1; Experimental Section). Complexes 1 – 4 were then prepared 
by stirring the dichloro(p-cym)ruthenium(II) dimer with the corresponding ligand (L6 – L9) in dry 
dichloromethane at ambient temperature and in the presence of triethylamine. All ligands and 
complexes were characterised by 1H and 13C NMR spectroscopy, and high-resolution ESI-MS 
(Experimental Section). 1H and 13C NMR spectra can be found in the Supporting Information (Figures 
S1 – S24), as well as the HR mass spectra (Figures S25 – S36). As an example, Figure 1 shows the 1H 
NMR spectra of L4 (bottom), L8 (middle), and complex 3 (top) in CDCl3. The lowest field region (9.5 – 
7.0 ppm) shows the aromatic protons of the indole-based substituent, followed by the region of the 
coordinated arene (5.5 – 4.0 ppm), and by the aliphatic region (4.0 – 0.5 ppm). Chemical shifts for 
the protons located near the ligand heteroatoms that bind to the metal can be observed, for 
example, the proton of the CH cyclohexyl bonded to the oxygen/sulfur (Figure 1) can be seen to shift 
upfield from the free ligand L8 to the metal complex 3. Such shifts  can be explained by the stereo-
electronic effects due to the coordination to the metal moiety, as previously observed.35 The signal 
for the NH proton is also no more visible after complexation, which confirms the successful synthesis 
of the complex. 
         
 
Figure 1. 1H NMR spectra of L4 (bottom), L8 (middle), and complex 3 (top) in CDCl3 (400 MHz). 
Residual solvents are marked with a cross. 
Crystals of ligand L5 and complexes 2 [(p-cym)Ru(O-Et-ind-th)Cl], 3 [(p-cym)Ru(O-Cy-ind-th)Cl], and 4 
([(p-cym)Ru(O-Ph-ind-th)Cl], suitable for X-ray structure determination, were obtained by slow 
diffusion of hexane into a saturated dichloromethane solution at 20 ºC. The crystallographic data 
and selected bond lengths and angles are given in Tables S1 – S12, and the crystal structures are 
shown in Figure 2 and Figure S40. Complexes 2-4 adopt a pseudo-octahedral structure with 
RuII bound to a η6-para-cymene ring, a N,S-chelated indole and chloride as ligands to form an 18-
electron complex with “piano-stool” geometry. 
 
         
Figure 2. Structures of ligand L5 (left) and RuII complex 4 (right). Thermal ellipsoids are drawn at the 
50% probability level. 
To investigate the stability of  complexes 1 – 4, the compounds were dissolved in a mixture (1:1) 
(v/v) of DMSO/RPMI and UV-Vis spectra were recorded over 24 h (Figure 3). The absorption band at 
420 nm gradually decreases while the one at 350 nm concomitantly increases, intersecting at the 
isosbestic point, which indicates that only the chloride and the hydrolysed forms of the complex 
contribute to the observed absorptions.40-43 The time dependence of the absorbance allows for the 
determination of the rate constants by plotting the absorbance versus time at fixed wavelength for 
each compound (Table 1). The hydrolysis rate depends on the ester group of the indole ligand. 
Complex 4 (the only complex containing an aromatic R substituent) presents the fastest hydrolysis. 
The rate of hydrolysis of complexes 1 – 3, with aliphatic R groups, suggests that the bulkier the R 
substituent is, the slower the aquation process is. 
 
Figure 3. UV−vis spectra of complex 2 in the mixture DMSO/RPMI over time (10-5 M, 298 K, 24 h). 
  
Aquation of the monodentate ligand X is a common behaviour for half-sandwich complexes of the 
type [(arene)M(NUS)X] and is usually considered an activation step, which allows further reactions 
with the corresponding targets.44-47 Solutions ranging from pH 7 to 12 were prepared using 0.1 M 
NaOH solution, and complexes 1 – 4 (previously dissolved in pure acetonitrile) were added to the 
corresponding solution with a known pH and mixed for 10 min. Spectra were recorded by UV-visible 
spectroscopy. The pKa values of the complexes were calculated using Origin 2019 by plotting the 
absorbance at the corresponding wavelength against the pH and fitting it to the Boltzmann equation 
to obtain the inflection point. For complexes 1 – 4, the pKa values were calculated to be around 10 
(Experimental section and Table 1). These pKa values are high, although such decrease in acidity has 
been previously reported (generally attributed to an increased electron density on the metal 
centre).44, 48, 49 As a consequence of such high pKa values, only the aqua adduct of the metal 
complexes is expected to be present at physiological pH (7.4), thus favouring the reaction between 
the metal complexes with possible ligands such as nucleobases or proteins. 
         
Table 1. Reactivity of complexes 1 – 4. pKa values measured using UV-Vis spectroscopy (10-5 M, 298 
K), solvent acetonitrile/water v/v. Aquation constants and rates of hydrolysis measured using UV-Vis 
spectroscopy (10-5 M, 298K), in a mixture (1:1) DMSO/RPMI v/v. 
Compound pKa Kaquation (s-1) 
[(p-cym)Ru(O-Me-ind-th)Cl] (1) 10.34 ± 0.07 2.0 x10-4 ± 6 x 10-5 
[(p-cym)Ru(O-Et-ind-th)Cl] (2) 10.24 ± 0.09 1.8 x10-4 ± 4 x 10-5 
[(p-cym)Ru(O-cy-ind-th)Cl] (3) 9.81 ± 0.07 1.2 x10-4 ± 3 x 10-5 
[(p-cym)Ru(O-ph-ind-th)Cl] (4) 10.07 ± 0.05 2.4 x10-4 ± 4 x 10-5 
 
Toxicity studies against human cells 
Toxicity data against human cells is important information for the identification of a novel family of 
antibiotic drug candidates. Initially developed for anticancer activity, complexes 1 – 4 (and ligands L6 
– L9) were tested against human ovarian adenocarcinoma (A2780), cisplatin-resistant variant of 
A2780 (A2780cisR) and normal human prostate epithelial (PNT2) cell lines. Half-maximal inhibitory 
concentrations (IC50) were determined using a 24 h MTT assay with 48 h recovery period. The IC50 
values are shown in table 2 and the IC50 graphs for ligands L6 – L9 and complexes 1 – 4 against PNT2, 
A2780, and A2780cisR can be found in the Supporting Information (Figures S37 – S38). 
Complexes 1, 2 and 3 are moderately cytotoxic against the tested cell lines and showed 2 – 3x higher 
IC50 values towards normal prostate cells in comparison to cancer cells. They are also less toxic than 
cisplatin against all cell lines. Complex 4 exhibits only low toxicity against the three cell lines.  
 
Table 2. IC50 values (µM) in A2780, A2780 cisplatin resistant and PNT2 cells for ligands L6 – L9 and 
for complexes 1 – 4. 
 IC50 values (µM) 
Compound A2780 A2780cisR PNT2 
L6 >100 >100 >100 
L7 >100 >100 >100 
L8 72 ± 2 76 ± 5 71 ± 5 
L9 21 ± 1 20 ± 2 26 ± 2 
1 22 ± 1 28 ± 1 32 ± 2 
2 12 ± 2 22 ± 2 37 ± 2 
3 10.7 ± 0.6 15.3 ± 0.9 20.8 ± 0.9 
4 68 ± 4 83 ± 3 96 ± 6 
cisplatin 5.9 ± 0.4 11.8 ± 0.8 26.1 ± 0.6 
 
Antibiotic activity 
A concentration range of complexes 1 – 4 were tested and activity was observed for a range of 
organisms, including Mycobacterium abscessus, Escherichia coli, Staphylococcus aureus, 
Acinetobacter baumannii, Salmonella enterica serovar Typhi and Mycobacterium tuberculosis. The 
minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) activity of 
all 4 complexes were determined (Tables 3 and 4).  Overall, complex 3 was the most effective, 
inhibiting 9 out of the 12 organisms tested. Complex 3 also had the lowest MIC observed for all 
         
complexes tested, at 1.56 µg/mL against S. aureus. Bactericidal activity was also observed against 7 
out of the 12 organisms tested (Figure 4). The 2 organisms that did not have an MBC were both 
mycobacterial species, M. abscessus and M. tuberculosis (Figure 4 and 6). However, complex 3 was 
bacteriostatic against both species of mycobacteria inhibiting at a concentration of 12.5 µg/mL and 
100 µg/mL, respectively. Complex 2 had similar inhibitory activity to complex 3, however no activity 
was observed for A. baumannii or E. coli I469 EBL (Table 3). Bactericidal activity for complex 2 was 
greatly reduced compared to complex 3 with an MBC observed for only S. typhi and S. aureus.  
Complex 1 was less effective, only inhibiting M. abscessus, M. tuberculosis, S. typhi and S. aureus. No 
bactericidal activity was observed for M. abscessus but bactericidal activity was observed for M. 
tuberculosis, S. tyhpi and S. aureus. Arguably complex 4 was the least effective, with an MIC and 
MBC observed for only S. aureus and M. tuberculosis (Figure 6). However, M. tuberculosis is a major 
human pathogen that is often highly drug resistant. Therefore, complex 4 is still of great potential 
importance and could be effective against other pathogens not yet tested.  
Table 3. The minimum inhibitory concentrations observed for all organisms tested. 
  Minimum Inhibitory Concentration (MIC) µg/mL 
Organism Complex 1 Complex 2 Complex 3 Complex 4 
Acinetobacter baumannii NCTC 
12156  





(94.5 µM) (>191.2 
µM) 
Escherichia coli ATCC 11775 >100 100 50 >100 
(>216.9 
µM) 
(210.5 µM) (94.5 µM) (>191.2 
µM) 





(94.5 µM) (>191.2 
µM) 
Escherichia coli J53 2138E >100 50 25 >100 
(>216.9 
µM) 
(105.2 µM) (47.25 µM) (>191.2 
µM) 
        
Escherichia coli J53 2140E >100 100 25 >100 
(>216.9 
µM) 
(210.5 µM) (47.25 µM) (>191.2 
µM) 
         





(<189 µM) (>191.2 
µM) 
Mycobacterium abscessus NCTC 
13031 
50 25 12.5 >100 
(108.4 µM) (52.6 µM) (23.6 µM) (>191.2 
µM) 
Mycobacterium tuberculosis H37Rv 50 100 100 50 
(108.4 µM) (210.5 µM) (189 µM) (95.6 µM) 





(<189 µM) (>191.2 
µM) 
Pseudomonas aueruginosa ATCC 
10145 





(<189 µM) (>191.2 
µM) 
Salmonella enterica serovar Typhi 50 25 6.25 >100 
(108.4 µM) (52.6 µM) (11.8 µM) (>191.2 
µM) 
Staphylococcus aureus ATCC 29213 6.25 12.5 1.56 12.5 








         
Table 4. The minimum bactericidal concentrations observed for all organisms tested. 
  Minimum Bactericidal Concentration (MBC) µg/mL 
Organism Complex 1 Complex 2 Complex 3 Complex 4 
Acinetobacter baumannii NCTC 
12156  





(94.5 µM) (>191.2 
µM) 





(94.5 µM) (>191.2 
µM) 





(94.5 µM) (>191.2 
µM) 





(47.25 µM) (>191.2 
µM) 





(47.25 µM) (>191.2 
µM) 





(<189 µM) (>191.2 
µM) 
Mycobacterium abscessus NCTC 
13031 





(<189 µM) (>191.2 
µM) 
Mycobacterium tuberculosis H37Rv 50 >100 >100 50 
(108.4 µM) (>210.5 
µM) 
(<189 µM) (95.6 µM) 
         





(<189 µM) (>191.2 
µM) 
Pseudomonas aueruginosa ATCC 
10145 





(<189 µM) (>191.2 
µM) 
Salmonella enterica serovar Typhi 50 25 6.25 >100 
(108.4 µM) (52.6 µM) (11.8 µM) (>191.2 
µM) 
Staphylococcus aureus ATCC 29213 12.5 12.5 3.125 50 




Figure 4 – The minimum bactericidal concentrations (MBC) for complex 3 identified by absence of 
growth. MBCs were defined by minimum concentration at which an absence of bacterial growth was 
observed after exposure to complex 3.  A, Acinetobacter baumannii ATCC 12156 had an MBC of 50 
µg/mL (n=3). B, Escherichia coli ATCC 11775 and C, E. coli ESBL had an MBC of 50 µg/mL (n=3). D, E. 
coli 2138E and E, E. coli 2140E both had MBCs of 25 µg/mL (n=3). F, Salmonella enterica serovar 
         
Typhi had an MBC of 6.25 µg/mL (n=3). G, Staphylococcus aureus exhibited an MBC of 3.125 µg/mL 
(n=3). H, plate map showing concentrations of complex 3. 
 
Growth curve data was obtained for M. abscessus (Figure 5) and analysed with an ANOVA. A 
significant difference between the different concentrations and controls was observed for 
complexes 1, 2 and 3 with P values of <0.0001 for all three complexes. No significant difference 
between concentrations and control were observed for complex 4. A multiple comparison was 
conducted for complexes 1, 2 and 3, which identified a significant difference between all 
concentrations and control (P value <0.0001) for all, apart from complex 1 at 3.125 µg/mL and the 
M. abscessus only control (P value 0.0064). This identifies that complexes 1, 2 and 3 are 
bacteriostatic against M. abscessus and have a significant impact on the growth. 
 
Figure 5 – Spectrophotometric growth curves of Mycobacterium abscessus with complexes 1 – 4 
showing bacteriostatic activity. (1) Activity of complex 1 against M. abscessus identifying the 
minimum inhibitory concentration (MIC) as 50 µg/mL (n=3). A one-way ANOVA was used on 
endpoint data and identified a significant difference between all concentrations and the control (p 
value <0.0001), apart from 3.125 µg/mL (p value 0.0064). (2) Complex 2 exhibited increased activity, 
with an MIC of 25 µg/mL (n=3). All concentrations were significantly different to the growth of M. 
abscessus only (p value <0.0001). (3) Complex 3 was the most effective of the complexes tested, 
inhibiting M. abscessus at 12.5 µg/mL (n=3). All concentrations impacted the growth of M. abscessus 
significantly (p value <0.0001). (4) Complex 4 had no MIC observed and did not significantly impact 
the growth of M. abscessus (n=3) (p value 0.2960). 
 
 




Figure 6 – Minimum Inhibitory Concentrations (MIC) (upper) and Minimum Bactericidal 
Concentrations (MBC) (lower) of Mycobacterium tuberculosis with complexes 1 – 4. (MBC images 
contrast adjusted to emphasise growth vs no growth). (1) Complex 1 shows an MIC with resazurin of 
50 µg/mL and an MBC on solid agar of 50 µg/mL (n=3). (2) Complex 2 shows an MIC with resazurin of 
100 µg/mL and no MBC on solid agar (>100 µg/mL) (n=3). (3) Complex 3 shows an MIC with resazurin 
of 100 µg/mL and no MBC on solid agar (>100 µg/mL) (n=3).(4) Complex 4 shows an MIC with 
resazurin of 50 µg/mL and an MBC on solid agar of 50 µg/mL (n=3).  
All four of the complexes inhibited a variety of microorganisms tested, with complex 3 being the 
most effective. The Gram-positive S. aureus was the most effected organism with the lowest MIC 
and MBC for all of the complexes tested, as well as being the only one, other than M. tuberculosis, 
affected by complex 4. Growth of M. tuberculosis was also inhibited by each complex, but at higher 
concentrations than for S. aureus. However, unlike S. aureus, complexes 2 and 3 had no bactericidal 
activity against M. tuberculosis. M. abscessus was largely inhibited by three out of the four 
complexes but had no bactericidal activity. A range of activity was identified for the Gram-negative 
organisms E. coli and S. typhi against complexes 1, 2 and 3, however no activity was observed for 
Proteus mirabilis, Pseudomonas aeruginosa or Klebsiella pneumonia.   
Conclusions 
In conclusion, four half-sandwich metal complexes containing a bioactive indole moiety were 
synthesised and characterised. They were progressed to in vitro screening to gain a first estimation 
of their cytotoxicity profile. The complexes only show moderate toxicity against A2780 ovarian 
cancer, A2780 cisplatin resistant, and PNT2 cell lines. As such, the bactericidal activity of the four 
compounds was investigated against several drug resistant isolates of Gram negative Escherichia coli 
and Salmonella enterica serovar Typhi as well as against isolates of Gram positive bacteria. 
All complexes showed growth inhibition and bactericidal activity against a variety of bacteria, 
including the notable pathogens M. tuberculosis, M. abscessus and E. coli. Complexes 2 and 3 exhibit 
the most promising antibacterial activities, having the lowest minimum inhibitory concentrations 
and exhibiting bactericidal activity. It appears that steric hindrance  of the R group on the indole has 
an influence on the aquation rate, the cytotoxicity, and the antibacterial properties, which will be 
         
confirmed/infirmed by future determination of the antibacterial mechanism of action. This series 
shows significant promise for further hit-to-lead medicinal chemistry, and future work will include 
further cytotoxicity studies, collection of in vivo data and mechanisms of action elucidation (target 
identification). 
Materials and methods 
Hydrated metallic chlorides were purchased from Precious Metals Online. All other chemicals were 
purchased from Sigma-Aldrich (UK). Non-dried solvents were purchased from Fischer Scientific and 
used as received. Dichloromethane, tetrahydrofuran and toluene were dried over molecular sieves 
(3 Å). All compounds were prepared under a purified dinitrogen atmosphere using standard Schlenk 
and vacuum line techniques, unless otherwise specified. pH* was adjusted using EDT direction non-
glass pocket pH meter with an ISFET silicon chip pH sensor. pH* values (pH readings without 
correction for the effect of deuterium) of NMR samples were adjusted using KOD solutions in D2O. 
All NMR spectra were recorded on a 400 MHz Bruker Spectrospin spectrometer using 5 mm NMR 
tubes. Data processing was carried out using TOPSPIN 4.0.9 (Bruker U.K. Ltd.). Deuterated solvents 
were purchased from Goss Scientific Instrument. 1H NMR chemical shifts were internally referenced 
to TMS via residual solvent peaks DMSO (δ = 2.52 ppm), CHCl3 (δ = 7.26 ppm), acetone (δ = 2.05 
ppm), THF (δ = 1.72 ppm) or MeOD (δ = 3.31 ppm). All UV-Vis spectra were recorded with Agilent 60 
Cary UV-Vis spectrophotometer. Ruthenium dimer [(p-cym)RuCl2]2 was synthesised using an Anton 
Paar microwave synthesis reactor (Monowave 300) and a 20 mL microwave vial equipped with a 
magnetic stirring bar.  
Roswell Park Memorial Institute (RPMI) 1640 medium, foetal bovine serum (FBS), penicillin and 
streptomycin, phosphate-buffered saline (PBS, pH 7.4), and other tissue culture reagents were 
purchased from Gibco (Thermo Fisher Scientific, UK). Cell lines were provided by the Institute of 
Cancer Therapeutics, University of Bradford. Cells were incubated in a ThermoScientific HERAcell 
150 incubator and observed under a Nikon ECLIPSE TS100 Microscope.  
Bacterial culture 
All chemicals and reagents were obtained from Sigma-Aldrich or Fisher Scientific, unless otherwise 
stated. The media used for Mycobacterium abscessus NCTC 13031 and Mycobacterium tuberculosis 
H37Rv was Middlebrook 7H9 broth with the addition of Albumin-Dextrose-Catalase (ADC) 
supplement (10%) and Tween80 (0.05%) and Middlebrook 7H11 agar with Oleic acid-Albumin-
Dextrose-Catalase (OADC) supplement (10%). The media used for all other organisms (Escherichia 
coli ATCC 11775, E. coli I469 ESBL, E. coli J53 2138E, E. coli J53 2140E, Klebsiella pneumonia H467 
KPC, Proteus mirabilis NCTC 8309, Pseudomonas aeruginosa ATCC 10145, Salmonella enterica 
serovar Typhi, Staphylococcus aureus ATCC 29213) was nutrient broth and nutrient agar. Prior to 
testing, all organisms were grown in broth to log phase at 37 °C with orbital shaking at 180 rpm. For 
M. abscessus this was 72 h, for M. tuberculosis this was 168 h and all other organisms 24 h.  
Synthesis and characterisation 
[Methyl indole-2-carboxylate] (L2). 1-H-indole-2-carboxylic acid (3.0 g, 18.6 mmol) was added to a 
round-bottom flask (100 mL) and dissolved in methanol (30 mL). Concentrated sulphuric acid (1.5 
mL, 28.0 mmol) was added to the mixture and subsequently heated to reflux for 2 h. Then, the 
         
solvent was removed under reduced pressure, and the crude was dissolved in ethyl acetate (6 mL), 
and subsequently extracted with a saturated solution of NaHCO3 (3 x 30 mL). The organic phases 
were combined and dried over MgSO4 and filtered. The filtrate was evaporated under vacuum to 
afford a light-brown powder (4.3 g, 93%). The synthesis and characterisation are in accordance with 
the literature.50 
 
1H NMR (DMSO-d6, 400 MHz): δ = 11.91 (1H, s, H1), 7.65 (1H, d, 
3JH-H = 8.0 Hz, H4), 7.45 (1H, d, 
3JH-H = 
8.3 Hz, H7), 7.26 (1H, dd, 3JH-H = 6.8 and 8.0 Hz, H6), 7.15 (1H, m, H3), 7.07 (1H, dd, 
3JH-H = 6.8 and 8.0 
Hz, H5), 3.87 ppm (3H, s, H11). 
13C{1H} NMR (DMSO-d6, 101 MHz): δ = 161.8 (C10), 137.4 (C2), 127.0 (C8 or C9), 126.7 (C8 or C9), 
124.7 (C6), 122.1 (C4), 120.2 (C5), 112.6 (C7), 107.8 (C3), 51.8 ppm (C11).  
HRMS (ESI+): m/z calc. for C10H10NO2 [M + H]
+ 176.0667; found 176.0702. 
[Ethyl indole-2-carboxylate] (L3). The procedure used to prepare L2 was followed with 30 mL of 
ethanol and 18.6 mmol of 1-H-indole-2-carboxylic acid. The pure compound L3 was obtained as a 
white powder (4.1 g, 91%). The synthesis and characterisation are in accordance with the 
literature.51 
 
1H NMR (DMSO-d6, 400 MHz): δ = 11.86 (1H, s, H1), 7.65 (1H, d, 
3JH-H = 8.0 Hz, H4), 7.45 (1H, d, 
3JH-H = 
8.4 Hz, H7), 7.25 (1H, dd, 3JH-H = 7.2 and 8.4 Hz, H6), 7.14 (1H, m, H3), 7.07 (1H, dd, 
3JH-H = 7.2 and 8.0 
Hz, H5), 4.34 (2H, q, 3JH-H = 7.1 Hz, H11), 1.34 ppm (3H, t,
 3JH-H = 7.0 Hz, H12). 
13C{1H} NMR (DMSO-d6, 101 MHz): δ = 161.3 (C10), 137.4 (C2), 127.3 (C8 or C9), 126.7 (C8 or C9), 
124.6 (C6), 122.1 (C4), 120.2 (C5), 112.6 (C7), 107.7 (C3), 60.4 (C11), 14.3 ppm (C12). 
HRMS (ESI+): m/z calc. for C10H10NO2 [M + H]
+ 190.0823; found 190.08564. 
 
[Cyclohexyl indole-2-carboxylate] (L4). The procedure used to prepare L3 was followed with 10 mL 
of cyclohexanol and 18.6 mmol of 1-H-indole-2-carboxylic acid. The pure compound L4 was obtained 
as a light-brown powder (4 g, 91%). 
 
         
1H NMR (DMSO-d6, 400 MHz): δ = 11.72 (1H, s, H1), 7.55 (1H, d, 
3JH-H = 8.0 Hz, H4), 7.37 (1H, d, 
3JH-H = 
8.4 Hz, H7), 7.16 (1H, dd, 3JH-H = 7.2 and 7.8 Hz, H6), 7.05 (1H, m, H3), 6.98 (1H, dd, 
3JH-H = 7.0 and 7.6 
Hz, H5), 4.86 (1H, m, H11), 1.86 – 1.15 ppm (10H, br, Hcyclohexane). 
13C{1H} NMR (DMSO-d6, 101 MHz): δ = 160.8 (C10), 137.4 (C2), 127.7 (C8 or C9), 126.8 (C8 or C9), 
124.6 (C6), 122.0 (C4), 120.1 (C5), 112.6 (C7), 107.7 (C3), 72.3 (C11), 31.2 (C12, C16), 25.0 (C14), 23.1 
ppm (C13, C15). 
HRMS (ESI+): m/z calc. for C15H18NO2 [M + H]
+ 244.1293; found 245.13568. 
[Phenyl indole-2-carboxylate] (L5). 1-H-indole-2-carboxylic acid (5.0 g, 31.0 mmol) was added to a 
round-bottom flask (100 mL). Phenol (2.92 g, 31.0 mmol), N,N-dimethyl-4-aminopyridine (DMAP, 1 
g, 8.19 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC, 8.0 g, 51.53 
mmol) and dry dichloromethane (60 mL) were added to the mixture and subsequently heated to 
reflux for 24 h. Then, the crude solution was quenched with a saturated aqueous solution of NaHCO3 
and extracted with H2O (3 x 30 mL). The organic phases were combined and dried over MgSO4 and 
filtered. The filtrate was evaporated under vacuum to afford a white powder (2.8 g, 37%). The 
synthesis and characterisation are in accordance with the literature.52 
 
 
1H NMR (DMSO-d6, 400 MHz): δ = 12.15 (1H, s, H1), 7.72 (1H, d, 
3JH-H = 8.0 Hz, H4), 7.49 (3H, dd, 
3JH-H 
= 8.8 and 9.2 Hz, H7, H13 and H15.), 7.41 (1H, m, H3), 7.32 (4H, m, H6, H12, H14 and H16), 7.13 ppm 
(1H, dd, 3JH-H = 7.4 and 7.6Hz, H5). 
13C{1H} NMR (DMSO-d6, 101 MHz): δ = 159.8 (C10), 150.3 (C11), 137.8 (C2), 129.6 (C13 and C15), 
126.7 (C8 or C9), 126.2 (C8 or C9), 126.0 (C6 or C14), 125.2 (C6 or C14), 122.3 (C4), 122.0 (C12 and 
C16.), 120.5 (C5), 112.7 (C7), 109.5 ppm (C3). 
HRMS (ESI+): m/z calc. for C15H12NO2 [M + H]
+ 238.0823; found 238.08532. 
[Methyl indole-2-thionoester] (L6). L2 (250 mg 1.43 mmol), and Lawesson’s reagent (693 mg, 1.7 
mmol) were added to a round-bottom flask and dissolved in toluene (35 mL). The mixture was 
refluxed for 6 days. The solution was cooled down and toluene was removed under reduced 
pressure. The crude was dissolved in ethyl acetate and extracted first with an aqueous saturated 
solution of NaHCO3, and then with brine, and dried over MgSO4 and filtered. The combined organic 
phases were brought to dryness, leaving a bright yellow oil, which was purified by column 
chromatography (hexane/ethyl acetate, 80:20 (v/v)). The solvent was removed under vacuum to 
give a bright yellow solid (203 mg, 74%). 
  
         
1H NMR (DMSO-d6, 400 MHz): δ = 11.75 (1H, s, H1), 7.67 (1H, d, 
3JH-H = 8.4 Hz, H4), 7.48 (1H, d, 
3JH-H = 
8.4 Hz, H7), 7.28 (2H, m, H3 and H6), 7.07 (1H, dd, 3JH-H = 7.6 and 8.0 Hz, H5), 4.24 ppm (3H, s, H11). 
13C{1H} NMR (DMSO-d6, 101 MHz): δ = 201.7 (C10), 138.4 (C2), 136.4 (C8 or C9), 126.9 (C8 or C9), 
125.6 (C6), 122.6 (C4), 120.6 (C5), 112.9 (C7), 107.2 (C3), 58.4 ppm (C11).  
HRMS (ESI+): m/z calc. for C10H10NOS [M + H]
+ 192.0483; found 192.0475. 
[Ethyl indole-2-thionoester] (L7). The procedure used to prepare L6 was followed with 250 mg (1.3 
mmol) of L3 and Lawesson’s reagent (623 mg, 1.57 mmol) and refluxed for 6 days. The pure 
compound L7 was obtained as a bright yellow solid (220 mg, 81%). 
 
1H NMR (DMSO-d6, 400 MHz): δ = 11.69 (1H, s, H1), 7.67 (1H, d, 
3JH-H = 8.4 Hz, H4), 7.49 (1H, d, 
3JH-H = 
8.4 Hz, H7), 7.28 (2H, m, H3 and H6), 7.07 (1H, dd, 3JH-H = 7.6 and 8.0Hz, H5), 4.70 (2H, q, 
3JH-H = 7.1 
Hz, H11), 1.47 ppm (3H, t, 3JH-H = 7.0 Hz, H12). 
13C{1H} NMR (DMSO-d6, 101 MHz): δ = 201.0 (C10), 138.3 (C2), 136.6 (C8 or C9), 126.9 (C8 or C9), 
125.6 (C6), 122.6 (C4), 120.6 (C5), 112.9 (C7), 107.1 (C3), 67.4 (C11), 13.7 ppm (C12). 
HRMS (ESI+): m/z calc. for C11H12NOS [M + H]
+ 206.0595; found 206.0632. 
[Cyclohexyl indole-2-thionoester] (L8). The procedure used to prepare L6 was followed with 250 mg 
(1.0 mmol) of L4 and Lawesson’s Reagent (499 mg, 1.23 mmol) and refluxed for 4 days. The pure 
compound L8 was obtained as a bright yellow solid (190 mg, 71%). 
 
1H NMR (DMSO-d6, 400 MHz): δ = 11.62 (1H, s, H1), 7.67 (1H, d, 
3JH-H = 8.0 Hz, H4), 7.49 (1H, d, 
3JH-H = 
8.0 Hz, H7), 7.28 (1H, dd, 3JH-H = 7.8 and 8.4 Hz, H6), 7.25 (1H, m, H3), 7.07 (1H,dd, 
3JH-H = 7.6 and 8.0 
Hz, H5), 5.58 (1H, m, H11), 2.05 – 1.33 ppm (10H, br, Hcyclohexane). 
13C{1H} NMR (DMSO-d6, 101 MHz): δ = 200.0 (C10), 138.3 (C2), 136.9 (C8 or C9), 126.9 (C8 or C9), 
125.5 (C6), 122.6 (C4), 120.6 (C5), 112.9 (C7), 107.0 (C3), 78.7 (C11), 30.4 (C12, C16), 24.9 (C14), 23.0 
ppm (C13, C15). 
HRMS (ESI+): m/z calc. for C15H18NOS [M + H]
+ 260.1064; found 260.1099. 
[Phenyl indole-2-thionoester] (L9): The procedure used to prepare L6 was followed with 250 mg 
(1.1 mmol) of L5 and Lawesson’s Reagent (511 mg, 1.26 mmol) and refluxed for 8 days. The pure 
compound L9 was obtained as a bright yellow solid (100 mg, 37%). 
         
  
1H NMR (DMSO-d6, 400 MHz): δ = 11.96 (1H, s, H1), 7.72 (1H, d, 
3JH-H = 8.0 Hz, H4), 7.55 – 7.48 (4H, 
m, H3, H7, H13 and H15), 7.37 – 7.32 (2H, m, H6 and H14), 7.24 (2H, d,
 3JH-H = 7.6 Hz, H12 and H16), 
7.11 ppm (1H, dd, 3JH-H = 7.6 and 8.0 Hz, H5). 
13C{1H} NMR (DMSO-d6, 101 MHz): δ = 200.0 (C10), 153.7 (C11), 138.9 (C2), 136.4 (C9 or C9), 129.7 
(C13 and C15), 127.0 (C8 or C9, 126.5 (C6 or C14), 126.3 (C6 or C14), 122.9 (C4), 122.4 (C12 and C16), 
120.9 (C5), 113.0 (C7), 108.9 ppm (C3). 
HRMS (ESI+): m/z calc. for C15H12NOS [M + H]
+ 254.0595; found 254.0631. 
[(p-cym)RuCl(methyl indole-2-thionoester)] (1). 
Ruthenium dimer [(p-cym)RuCl2]2 (70 mg, 0.11 mmol) and L6 (46 mg, 0.24 mmol) were placed in a 50 
mL round-bottom flask and dissolved in 15 mL of dry dichloromethane. Once dissolved, 62 L of dry 
triethylamine (0.46 mmol) were added to the mixture. The bright orange mixture was stirred under 
nitrogen overnight at 25 ℃, until a brown solution was obtained. The crude was extracted with an 
aqueous solution of 0.1 M HCl (3 x 10 mL) and the combined organic phases were dried over MgSO4 
and filtered. The product was purified by column chromatography (ethyl acetate/hexane 60:40 (v/v)) 
and recrystallised in dichloromethane/hexane to obtain a bright red solid (30 mg, 58%). 
  
1H NMR (CDCl3, 400 MHz): δ = 7.59 (1H, d, 
3JH-H = 8.4 Hz, H13), 7.56 (1H, d, 
3JH-H = 8.4 Hz, H16), 7.22 
(1H, dd, 3JH-H = 6.8 and 8.0, H15), 7.07 (1H, s, H12), 6.96 (1H, dd, 
3JH-H = 6.8 and 8.0 Hz, H14), 5.83 (2H, 
q, 3JH-H = 6.2 Hz, H3 and H4), 5.72 (1H, d, 
3JH-H = 5.8 Hz, H6), 5.58 (1H, d, 
3JH-H = 6.0 Hz, H5), 4.37 (3H, s, 
H20), 2.53 (1H, sept, 3JH-H = 6.9 Hz, H8), 2.25 (3H, s, H1), 1.07 (3H, d, 
3JH-H = 6.9 Hz, H10), 0.92 ppm 
(3H, d, 3JH-H = 6.9 Hz, H9). 
13C{1H} NMR (CDCl3, 101 MHz): δ = 206.6 (C19), 152.0 (C11), 144.4 (C17 or C18), 130.9 (C17 or C18), 
125.5 (C15), 124.5 (C13), 120.0 (C14), 116.8 (C16), 108.2 (C12), 103.0 (C7), 102.3 (C2), 85.9 (C6), 83.7 
(C3 or C4), 83.2 (C3 or C4), 82.0 (C5), 60.1 (C20), 31.1 (C8), 23.0 (C10), 21.8 (C9), 19.0 ppm (C1). 
HRMS (ESI+): m/z calc. for C20H22NORuS [M - Cl]
+ 426.0466; found 426.0452. 
[(p-cym)RuCl(ethyl indole-2-thionoester)] (2). 
Complex 2 was synthesised following the procedure of complex 1 with L7 (50 mg, 0.24 mmol). The 
pure compound 2 was obtained as a bright red solid (30 mg, 56%). 
         
  
1H NMR (CDCl3, 400 MHz): δ = 7.58 (2H, m, H13, H16), 7.21 (1H, dd, 
3JH-H = 6.8 and 8.0 Hz, H15), 7.08 
(1H, s, H12), 6.96 (1H, dd, 3JH-H = 6.8 and 7.6 Hz, H14), 5.82 (2H, q, 
3JH-H = 6.0 Hz, H3, H4), 5.71 (1H, d, 
3JH-H = 5.9 Hz, H6), 5.56 (1H, d, 
3JH-H = 5.9 Hz, H5), 4.74 (2H, q , 
3JH-H = 7.1 Hz, H20), 2.53 (1H, sept, 
3JH-H 
= 6.9 Hz, H8), 2.25 (3H, s, H1), 1.55 (3H, t, 3JH-H = 7.0 Hz, H21), 1.07 (3H, d, 
3JH-H = 7.2 Hz, H10), 0.92 
ppm (3H, d, 3JH-H = 6.9 Hz, H9). 
13C{1H} NMR (CDCl3, 101 MHz): δ = 205.8 (C19), 151.9 (C11), 144.5 (C17 or C18), 130.9 (C17 or C18), 
125.3 (C15), 124.5 (C13), 119.9 (C14), 116.8 (C16), 108.0 (C12), 103.0 (C7), 102.1 (C2), 85.9 (C6), 83.7 
(C3 or C4), 83.2 (C3 or C4), 82.0 (C5), 69.8 (C20), 31.1 (C8), 23.0 (C10), 21.8 (C9), 19.1 (C1), 14.4 ppm 
(C21). 
HRMS (ESI+): m/z calc. for C21H24NORuS [M - Cl]
+ 440.0622; found 440.0614. 
[(p-cym)RuCl(cyclohexyl indole-2-thionoester)] (3). 
Complex 3 was synthesised following the procedure of complex 1 with L8 (62 mg, 0.24 mmol). The 
pure compound 3 was obtained as a bright red solid (39 mg, 65%). 
 
1H NMR (CDCl3, 400 MHz): δ = 7.58 (2H, m, H13, H16), 7.21 (1H, dd, 
3JH-H = 6.8 and 8.0 Hz, H15), 7.07 
(1H, s, H12), 6.95 (1H, dd, 3JH-H = 6.8 and 7.6 Hz, H14), 5.80 (2H, m, H3, H4), 5.70 (1H, d, 
3JH-H = 6.0 Hz, 
H6), 5.55 (1H, d, 3JH-H = 5.9 Hz, H5), 5.37 (1H, m, H20), 2.52 (1H, sept, 
3JH-H = 6.9 Hz, H8), 2.25 (3H, s, 
H1), 2.20 – 1.24 (10H, br, Hcyclohexane), 1.07 (3H, d, 
3JH-H = 7.0 Hz, H10), 0.93 ppm (3H, d, 
3JH-H = 7.0 Hz, 
H9). 
13C{1H} NMR (CDCl3, 101 MHz): δ = 204.8 (C19), 151.8 (C11), 145.0 (C17 or C18), 130.8 (C17 or C18), 
125.2 (C15), 124.4 (C13), 119.8 (C14), 116.8 (C16), 107.9 (C12), 103.0 (C7), 101.9 (C2), 85.9 (C6), 83.8 
(C3 or C4), 83.3 (C3 or C4), 82.9 (C20), 82.0 (C5), 31.5 (CH2cyclohex.), 31.1 (C8), 25.4 (CH2cyclohex.), 23.7 
(2CH2cyclohex.), 23.6 (CH2cyclohex.) 22.9 (C10), 21.8 (C9), 19.0 ppm (C1). 
HRMS (ESI+): m/z calc. for C25H30NORuS [M - Cl]
+ 494.1092; found 494.1088. 
[(p-cym)RuCl(phenyl indole-2-thionoester)] (4). 
         
Complex 4 was synthesised following the procedure of complex 1 with L9 (61 mg, 0.24 mmol). The 
pure compound 4 was obtained as a bright red solid (31 mg, 51%). 
  
1H NMR (CDCl3, 400 MHz): δ= 7.63 (1H, d, 
3JH-H = 8.2 Hz, H13), 7.57 (1H, d, 
3JH-H = 8.7 Hz, H16), 7.48 
(2H, m, H22 and H24), 7.37 (1H, t, 3JH-H = 7.4 Hz, H23), 7.29 – 7.21 (4H, m, H12, H15, H21 and H25), 
6.99 (1H, dd, 3JH-H = 6.4 and 8.0 Hz, H14), 5.83 (1H, d, 
3JH-H = 6.0 Hz, H4), 5.80 (1H, d, 
3JH-H = 6.0 Hz, 
H3), 5.64 (1H, d, 3JH-H = 5.9 Hz, H6), 5.49 (1H, d, 
3JH-H = 5.9 Hz, H5), 2.49 (1H, sept, 
3JH-H = 6.9 Hz, H8), 
2.24 (3H, s, H1), 1.06 (3H, d, 4JH-H = 7.0 Hz, H10), 0.94 ppm (3H, d, 
4JH-H = 7.0 Hz, H9). 
13C{1H} NMR (CDCl3, 101 MHz): δ = 204.9 (C19), 154.8 (C20), 153.0 (C11), 144.8 (C17 or C18), 131.1 
(C17 or C18), 130.0 (C22 and C24), 127.2 (C23), 126.2 (C15), 124.9 (C13), 122.0 (C21 and C25), 120.4 
(C14), 116.9 (C16), 109.5 (C12), 103.3 (C7), 102.1 (C2), 85.9 (C6), 83.9 (C4), 83.5 (C3), 81.8 (C5), 31.1 
(C8), 22.8 (C10), 21.9 (C9), 19.0 ppm (C1). 
HRMS (ESI+): m/z calc. for C25H24NORuS [M - Cl]
+ 488.0622; found 488.0617. 
Solution chemistry 
Stability determination: Complexes 1 – 4 were dissolved in MeOD (2.2 mM) and diluted to a final 
concentration of 1.1 mM with either MeOD or D2O. 
1H NMR spectra were recorded at t  10 min, 12 
h and 24 h. 
pKa determination: Complexes 1 – 4 were dissolved in acetonitrile/H2O 6:94 (v/v) and UV-Vis spectra 
of the sample were recorded increasing the pH from 7 to 12. pKa value of each complex was 
determined using Origin 2019 by plotting the absorbance against the pH. 
Hydrolysis rate: Complexes 1 – 4 were dissolved in DMSO/RPMI 1:1 (v/v) (3 x 10-5 M) at room 
temperature and UV-Vis spectra of the samples were recorded at different times between t  10 min 
and 24 h. The dissociation constant values were calculated using Origin 2019 by plotting the 
absorbance against the time at fixed wavelength. 
Chemosensitivity Assays 
In vitro chemosensitivity tests were performed against A2780, A2780cisR and PNT2 cells. Cancer cell 
lines were routinely maintained as monolayer cultures in RPMI medium supplemented with 10% 
foetal calf serum, penicillin (100 I.U./mL) and streptomycin (100 μg/mL), sodium pyruvate (1 mM) 
and L-glutamine (2 mM). For chemosensitivity studies, cells were incubated in 96-well plates at a 
concentration of 7.5 × 103 cells per well and the plates were incubated for 24 h at 37 °C and a 5% 
CO2 humidified atmosphere prior to drug exposure. 
Complexes were dissolved in dimethylsulfoxide (DMSO) to provide stock solutions which were 
further diluted with media to provide a range of final concentrations. Drug-media solutions were 
         
added to cells (the final concentration of DMSO was less than 1% (v/v) in all cases) and incubated for 
24 h at 37 °C and 5% CO2 humidified atmosphere. The drug-media was removed from the wells and 
the cells were washed with PBS (100 μL, twice), and 100 μL of complete fresh media were added to 
each well. The plates were further incubated for 48 h at 37 °C in a 5% CO2 humidified atmosphere to 
allow for a period of recovery. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
(20 μL, 2.5 mg/mL) was added to each well and incubated for 2 h at 37 °C and 5% CO2 humidified 
atmosphere. All solutions were then removed and 100 μL of DMSO was added to each well in order 
to dissolve the purple formazan crystals. A Thermo Scientific Multiskan EX microplate photometer 
was used to measure the absorbance in each well at 570 nm. Cell survival was determined as the 
absorbance of treated cells divided by the absorbance of controls and expressed as a percentage. 
The IC50 values were determined from plots of % survival against drug concentration. Each 
experiment was repeated in triplicates of triplicates and a mean value was obtained and stated as 
IC50 (μM) ± SD. Cisplatin was also used as a positive control. 
Bacterial susceptibility testing 
A broth microdilution assay was used to determine antimicrobial activity of the compounds. Briefly, 
complexes 1-4 were made up to a stock solution of 10 mg/mL in DMSO (dimethylsulphoxide) and 
serially diluted in 96 well plates to final concentrations of 100 µg/mL, 50 µg/mL, 25 µg/mL, 12.5 
µg/mL, 6.25 µg/mL and 3.125 µg/mL. All bacterial suspensions (except M. tuberculosis) were 
adjusted to an optical density (OD600) of 0.1 prior to inoculation. An initial spectrophotometric read 
was taken using a Biotek EL808 plate reader at 570 nm. The plates were then incubated at 37 °C and 
read every 24 h for the length of the assay (M. abscessus = 96 h, all other organisms = 24 h). Once 
the spectrophotometric assays were complete, 5 µL of each well was plated out onto appropriate 
agar and incubated at 37 °C for 24-48 h to check for bactericidal activity.  All data was processed 
through GraphPad Prism 8.   
M. tuberculosis was assessed by addition of OD600 adjusted culture (OD600=0.001) to experimental 
wells containing serially diluted complexes 1-4 (as previously described). Plates were incubated for 
168 h at 37 °C, before 5 µL of each experimental well was plated onto Middlebrook 7H11 agar with 
OADC. These agar plates were incubated at 37 °C for 312 h. The drug containing 96-well plates were 
also additionally incubated for a further 240 h at 37 °C, after which resazurin (0.0025%) was added 
and plates were incubated at 37 °C for a final 24 h. Minimum inhibitory concentrations were 
determined by conversion of resazurin to resorufin. Minimum bactericidal concentrations were 
determined by the lowest concentration in which no growth was visibly seen on the solid agar 
plates.  
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